
The temptation to use uncontrolled, early, small studies to support further development of products may prove problematic for emerging biopharma companies.
Phillip Ward is the European editor of Applied Clinical Trails.
The temptation to use uncontrolled, early, small studies to support further development of products may prove problematic for emerging biopharma companies.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Significant differences exist in the characteristics of the priority review drugs approved by the FDA and the European Medicines Agency.
Published: May 29th 2015 | Updated:
Published: July 13th 2015 | Updated:
Published: February 2nd 2017 | Updated: